Third Quarter 2020 Results

Bayer AG News Conference Call

Challenging third quarter – Group outlook confirmed
  • Group sales decrease by 5.1 percent (Fx & portfolio adj.) to 8.506 billion euros
  • EBITDA before special items falls 21.4 percent to 1.795 billion euros
  • Substantial decline in sales and earnings at Crop Science, heavily impacted by seasonal and currency effects
  • Pharmaceuticals business recovering – higher earnings but slightly lower sales
  • Strong performance at Consumer Health
  • Net loss of 2.744 billion euros – impairment charges at Crop Science, proceeds from divestment of Animal Health
  • Core earnings per share decline by 30.2 percent to 0.81 euros
  • Free cash flow falls by 2.1 percent to 1.237 billion euros


Follow us:



   You will find the key statements on » Twitter